{"id":"NCT00310375","sponsor":"GlaxoSmithKline","briefTitle":"Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial","officialTitle":"A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05-01","primaryCompletion":"2016-11-30","completion":"2017-03-15","firstPosted":"2006-04-03","resultsPosted":"2016-11-25","lastUpdate":"2020-07-31"},"enrollment":181,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Ezogabine: USAN Retigabine (International Nonproprietary Name)","otherNames":["GKE-841","D-23129","GW582892X"]}],"arms":[{"label":"Ezogabine: USAN Retigabine (International Nonproprietary Name)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the VRX-RET-E22-301 double-blind study. The efficacy of long-term treatment with retigabine and patient quality of life will also be assessed.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Serious Adverse Event (SAE) and Adverse Event (AE)","timeFrame":"Assessed up to a maximum of 9 years","effectByArm":[{"arm":"Overall Study","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":51,"countries":["United States","Argentina","Brazil","Canada","Mexico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":181},"commonTop":["Dizziness","Somnolence","Headache","Urinary tract infection","Influenza"]}}